Vaccine candidates based on MVA viral vectors expressing VP2 or VP7 confer full protection against Epizootic hemorrhagic disease virus in IFNAR(−/−) mice

  • Jiménez-Cabello L
  • Utrilla-Trigo S
  • Rodríguez-Sabando K
  • et al.
5Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Emergence and re-emergence of arthropod-borne viruses are major concerns for both human and animal health. The most recent example is the fast expansion of EHDV-8 through Europe. Besides, EHDV-8 relates with a high prevalence of pathologic cases in cattle populations. No vaccine is currently available in Europe, and vaccine research against this arboviral disease is negligible. In this work, we present novel DIVA vaccine candidates against EHDV, and most importantly, we identified the protein VP7 of EHDV as an antigen capable of inducing multiserotype protection, one of the major challenges in vaccine research against orbiviruses.

Cite

CITATION STYLE

APA

Jiménez-Cabello, L., Utrilla-Trigo, S., Rodríguez-Sabando, K., Carra-Valenzuela, A., Illescas-Amo, M., Calvo-Pinilla, E., & Ortego, J. (2024). Vaccine candidates based on MVA viral vectors expressing VP2 or VP7 confer full protection against Epizootic hemorrhagic disease virus in IFNAR(−/−) mice. Journal of Virology, 98(12). https://doi.org/10.1128/jvi.01687-24

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free